Prostate cancer (PCa) is a prevalent malignancy that occurs primarily in old males. Prostate
tumors in different patients manifest significant inter-patient heterogeneity with respect to …

Prostate cancer is the second most common malignancy in men and androgen deprivation
therapy is the first‐line therapy. However, most cases will eventually develop castration …

Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …

The discovery that androgens play an important role in the progression of prostate cancer
led to the development of androgen deprivation therapy (ADT) as a first line of treatment …

The discovery of the benefits of castration for prostate cancer treatment in 1941 led to
androgen deprivation therapy, which remains a mainstay of the treatment of men with …

Prostate cancer (PC) is driven by androgen receptor (AR) activity, a master regulator of
prostate development and homeostasis. Frontline therapies for metastatic PC deprive the …

Mutations of the androgen receptor (AR) associated with prostate cancer and androgen
insensitivity syndrome may profoundly influence its structure, protein interaction network …

Abstract Background Nectin-4 and Trop-2 are transmembrane targets of FDA-approved
antibody-drug conjugates (ADC) Enfortumab-vedotin (EV) and Sacituzumab govitecan (SG) …

Cyclic high-dose testosterone administration, known as bipolar androgen therapy (BAT), is a
treatment strategy for patients with metastatic castration-resistant prostate cancer (mCRPC) …

Prostate cancer (CaP) remains the second leading cause of cancer deaths in Western men.
These deaths occur because metastatic CaP acquires resistance to available treatments …